Alteration of Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting Status in Prostate Cancer by Kingshott, Georgina G et al.
                          Kingshott, G. G., Biernacka, K. M., Sewell, A. W., Barker, R. M.,
Zielinska, H. A., Mccarthy, K., Martin, R. M., Lane, J. A., Rowe, E.,
Oxley, J., Holly, J. M. P., & Perks, C. M. (2021). Alteration of
Metabolic Conditions Impacts the Regulation of IGF-II/H19 Imprinting
Status in Prostate Cancer. Cancers, 13(4), 1-18. [825].
https://doi.org/10.3390/cancers13040825
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3390/cancers13040825
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via MDPI at
https://doi.org/10.3390/cancers13040825 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the




Alteration of Metabolic Conditions Impacts the Regulation of
IGF-II/H19 Imprinting Status in Prostate Cancer
Georgina Kingshott 1,*,† , Kalina Biernacka 1,†, Alex Sewell 2, Paida Gwiti 2,3, Rachel Barker 1 ,
Hanna Zielinska 1, Amanda Gilkes 4, Kathryn McCarthy 5, Richard M. Martin 6,7, J. Athene Lane 8 ,
Lucy McGeagh 9, Anthony Koupparis 10, Edward Rowe 10, Jon Oxley 2 , Jeff M. P. Holly 1,‡ and
Claire M. Perks 1,‡


Citation: Kingshott, G.; Biernacka,
K.; Sewell, A.; Gwiti, P.; Barker, R.;
Zielinska, H.; Gilkes, A.; McCarthy,
K.; Martin, R.M.; Lane, J.A.; et al.
Alteration of Metabolic Conditions
Impacts the Regulation of
IGF-II/H19 Imprinting Status in
Prostate Cancer. Cancers 2021, 13, 825.
https://doi.org/10.3390/
cancers13040825
Received: 12 January 2021
Accepted: 9 February 2021
Published: 16 February 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 IGF & Metabolic Endocrinology Group, Translational Health Sciences, Bristol Medical School, Learning &
Research Building, Southmead Hospital, Bristol BS10 5NB, UK; mdxkz@bristol.ac.uk (K.B.);
mdrmh@bristol.ac.uk (R.B.); hanna.zielinska@hotmail.com (H.Z.); jeff.holly@bristol.ac.uk (J.M.P.H.);
claire.m.perks@bristol.ac.uk (C.M.P.)
2 Department of Cellular Pathology, North Bristol NHS Trust, Southmead Hospital, Bristol BS10 5NB, UK;
alexsewell@doctors.org.uk (A.S.); paida@doctors.org.uk (P.G.); jon.oxley@nbt.nhs.uk (J.O.)
3 Department of Pathology, North West Anglia NHS Foundation Trust, Peterborough PE3 9GZ, UK
4 Department of Haematology, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; gilkes@cardiff.ac.uk
5 Department of Surgery, Department of Medicine, Southmead Hospital, Bristol BS10 5NB, UK;
Kathryn.mccarthy@nbt.nhs.uk
6 Population Health Sciences, Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road,
Bristol BS8 2PS, UK; richard.martin@bristol.ac.uk
7 National Institute for Health Research, Biomedical Research Centre at University Hospitals Bristol and
Weston NHS Foundation Trust and the University of Bristol, Biomedical Research Unit Offices,
University Hospitals Bristol Education Centre, Dental Hospital, Lower Maudlin Street, Bristol BS1 2LY, UK
8 Bristol Randomised Trials Collaboration, Population Health Sciences, Bristol Medical School,
University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK; athene.lane@bristol.ac.uk
9 Supportive Cancer Care Research Group, Faculty of Health and Life Sciences, Oxford Institute of Nursing,
Midwifery and Allied Health Research, Oxford Brookes University, Jack Straws Lane, Marston,
Oxford OX3 0FL, UK; lmcgeagh@brookes.ac.uk
10 Department of Urology, Bristol Urological Institute, Southmead Hospital, Bristol BS10 5NB, UK;
anthony.koupparis@nbt.nhs.uk (A.K.); edward.rowe@nbt.nhs.uk (E.R.)
* Correspondence: gk16114@bristol.ac.uk
† These authors contributed equally to this paper as first authors.
‡ These authors contributed equally to this paper as senior authors.
Simple Summary: Insulin-like growth factor II (IGF-II) is a potent growth factor implicated in several
cancer types. The IGF-II gene shares its locus with the long non-coding RNA, H19. IGF-II/H19 is
an imprinted gene—a phenomenon where only the maternal copy is expressed. The silencing of
the paternal copy is lost in many cancer types—including prostate. Our in vitro findings show it is
possible to disrupt imprinting through the alteration of metabolic conditions, with changes occurring
at the molecular level only. Comparing with prostate tissue samples we additionally found a positive
correlation to exist between IGF-II and H19 mRNA expression, which was further confirmed by in
silico data from the Cancer Genome Atlas.
Abstract: Prostate cancer is the second major cause of male cancer deaths. Obesity, type 2 diabetes,
and cancer risk are linked. Insulin-like growth factor II (IGF-II) is involved in numerous cellular
events, including proliferation and survival. The IGF-II gene shares its locus with the lncRNA, H19.
IGF-II/H19 was the first gene to be identified as being “imprinted”—where the paternal copy is not
transcribed—a silencing phenomenon lost in many cancer types. We disrupted imprinting behaviour
in vitro by altering metabolic conditions and quantified it using RFLP, qPCR and pyrosequencing;
changes to peptide were measured using RIA. Prostate tissue samples were analysed using ddPCR,
pyrosequencing and IHC. We compared with in silico data, provided by TGCA on the cBIO Portal.
We observed disruption of imprinting behaviour, in vitro, with a significant increase in IGF-II
and a reciprocal decrease in H19 mRNA; the increased mRNA was not translated into peptides.
In vivo, most specimens retained imprinting status apart from a small subset which showed reduced
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imprinting. A positive correlation was seen between IGF-II and H19 mRNA expression, which
concurred with findings of larger Cancer Genome Atlas (TGCA) cohorts. This positive correlation
did not affect IGF-II peptide. Our findings show that type 2 diabetes and/or obesity, can directly
affect regulation growth factors involved in carcinogenesis, indirectly suggesting a modification of
lifestyle habits may reduce cancer risk.
Keywords: IGF2; H19; imprinting; cancer; inflammatory markers
1. Introduction
Prostate cancer is the most frequently diagnosed cancer type and the second major
cause of cancer deaths amongst men [1]. Whilst the exact cause of prostate cancer remains
unknown, several factors have been found to contribute to disease susceptibility, progres-
sion, and prognosis. These include familial history and genetics [2], ethnicity [3], ageing [4]
and obesity [5].
In families with a history of prostate cancer, the risk of developing the disease doubles
in those with a first-degree relationship [6]. In terms of heritability, it appears that pre-
disposition to the disease is not caused by changes to a single gene; it is due to polygenic
mutations [7,8].
Numerous studies have highlighted the disparities in prostate cancer incidence across
the globe, focusing on populations in developed and developing countries. The clear link
between most is that the incidence of prostate cancer is highest amongst men of Afro
Caribbean origin [9,10].
A link exists between obesity and cancer risk [11]. The increased adipose tissue,
associated with obesity, produces over 20 hormones and cytokines that can disturb the
delicate balance of the cellular environment [12].
In addition to increased cancer risk, obesity also increases susceptibility to type
2 diabetes (T2D). [13]. One key characteristic associated with T2D is hyperglycaemia. As
glucose is the main energy source for cells, including cancer cells, an increase in its supply
can cause increased proliferative potential [14]. Moreover, a study published in 2019 found
a strong link between hyperglycaemia and increased risk of fatal prostate cancer [15].
Insulin-like growth factor II (IGF-II) is a growth factor expressed in high quantities
during early embryonic development [16]. Expression continues throughout adulthood,
with the liver being the primary site of synthesis [17]. IGF-II plays a critical role in several
cellular events, including proliferation and survival [18].
In obese subjects, circulating serum levels of IGF-II are elevated and have shown a
positive correlation with increased body mass index (BMI) [19]. Conversely, after weight
loss, circulating levels of IGF-II have been shown to drop, regardless of which diet was
followed [20].
The IGF-II/H19 gene is located on the short arm of chromosome 11p.15.5 [21]. It is
composed of 10 exons and contains 5 promoters. Exons 1–4 and 6 are non-coding. Control
of expression takes place from promoters 0 to 4 and is strictly regulated. 128 kb downstream
from IGF-II is a long non-coding RNA, H19, which is linked to IGF-II by an imprinting
control region (ICR) [22].
IGF-II was the first gene identified to be “imprinted” [23]. This is a heritable epigenetic
event whereby, through changes to the DNA structure (such as methylation or histone
modification) one parental copy will be silenced or imprinted [24]. The loss of this natural
silencing phenomenon (loss of imprinting—LOI) has been identified across a number of
cancers, including prostate [25], breast [26], colorectal [27] and lung [28].
Several suggested models for the imprinting mechanism have been proposed, with the
most widely accepted being the “enhancer competition model” [29]. This model proposes
that the presence of a CCCTC-binding factor (CTCF)—a multi-zinc finger protein (and
a transcriptional repressor)—can bind to the unmethylated imprint control region (ICR)
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embedded within the maternal IGF-II / H19 allele. This impedes IGF-II transcription.
Conversely, on the paternal allele, the ICR is hypermethylated. This blocks CTCF from
binding, which permits IGF-II to be transcribed. It is thought that loss of imprinting occurs
when both parental copies of IGF-II / H19 are hypermethylated at the ICR, resulting in the
bi-allelic expression of IGF-II [30].
The function of H19 has been the subject of many conflicting reports. In some cancers,
it behaves as an oncogene. For example, in gastric cancer, H19 and an embedded micro
RNA (miRNA-675) within its first exon, were found to be increased in tissue and cell lines.
This over-expression led to increased cell proliferation and the inhibition of apoptosis [31].
In non-small-cell lung cancer (NSCLC), H19 expression was significantly higher in NSCLC
lung tissue compared with normal, being at its highest in those from stage III and IV tu-
mours [32]. In contrast, it has been found to behave as a tumour suppressor in some cancer
types, such as colorectal [33] and prostate [34]. The mechanism that dictates H19 behaviour
differs between cancer types.
A study conducted in 2011 [35] analysed LOI of IGF-II in human prostates containing
cancerous cells. Using qPCR and pyrosequencing, LOI occurred not only in cells adjacent to
tumours but also in distant areas within the peripheral region. This suggests a widespread
epigenetic field effect in histologically normal tissues.
One study, published in 2012, analysed circulating IGF-II protein levels [36] in patients
with a history of PCa. Of 106 (41 patients—radical prostatectomised (RPE)—and 65 controls)
IGF-II levels were significantly elevated in the RPE cohort. LOI was also significantly higher
in the RPE group (39%) compared to the control (20%). Despite the link between LOI and
elevated serum IGF-II in the RPE group, the two were found to be uncoupled. Of the
control cohort with LOI (20%), circulating IGF-II levels were found to be very similar to
those of the RPE cohort with LOI (39%). Based on these findings, the authors suggested that,
under normal conditions, only approximately 35% of the total serum IGF-II is regulated by
imprinting [36].
A previous report focused on promoter methylation as a factor contributing to IGF-
II transcription [37]. IGF-II mRNA and peptide levels were decreased by 80% of PCa,
compared to non-neoplastic adjacent prostate and were independent of LOI status. IGF-
II expression in both tumour and adjacent tissue depended on the usage of the IGF-II
promoters P3 and P4; decreased IGF-II expression in tumour tissue was strongly related to
hypermethylation of these two promoters. The cause of hyper-methylation in this cohort
was attributed to cumulative DNA damage, as a result of ageing.
In this study, we examined the in vitro effects of altering metabolic conditions on IGF-II
imprinting status, IGF-II / H19 mRNA, and IGF-II peptide levels in the PC3 prostate cancer
cell line. In addition, a comparative clinical cohort of prostate cancer tissue was analysed
for expression of IGF-II and H19 mRNA using digital droplet polymerase chain reaction
(ddPCR) and compared with two larger publicly available patient cohorts from the Cancer
Genome Atlas (TGCA). IGF-II imprinting status was also analysed, using pyrosequencing,
along with IGF-II localisation and abundance using immunohistochemistry (IHC).
2. Results
2.1. Identification of Prostate Cell Line Suitability
To enable us to study the effects of metabolic conditions on LOI of IGF-II, we needed to
select a suitable cell line; DNA was extracted from 4 immortalised prostate cancer cell lines:
PC3, LNCaP, DU145, VcaP and 1 normal prostate cell line: PNT2. These were genotyped
using restriction fragment length polymorphism (RFLP) digestion at the APA1 restriction
site (rs680); VcaP and PC3 cells were found to be heterozygous, presenting with 2 bands
of sizes 292 bp and 229 bp, respectively (Figure 1A). These cell lines were classified as
informative and would be suitable for further assessment of imprinting status. Cell lines
DU145, PNT2 and LNCaP were found to be homozygous for the SNP at rs680 (i.e., the
same snp base at the same location, on both copies of the gene), resulting in a single band
pattern and, as such, were deemed non-informative.
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Figure 1. Genotyping, IGF-II allelic expression and imprinting behaviour after treatment with glucose, in prostate cancer 
cell lines using APA1 RFLP, PIE and qPCR analyses. (A) Gel image depicting genotype results of cell lines VcaP, 
DU145, PNT2, LNCaP and PC3. VcaP and PC3 showed two bands, sized 292- and 229 bp. This meant that 
these cells were heterozygous for the SNP at rs680 and, therefore, informative. (n = 3). (B) Gel image depicting 
IGF-II allelic expression. The VcaP cell line showed two bands, sized 292 and 229 bp, signifying bi-allelic ex-
pression and, therefore, loss of imprinting of IGF-II. The PC3 cell line showed a single band sized 292 bp, 
indicating mono-allelic expression of IGF-II and, therefore, a retention of imprinting status. (n = 3). (C) Gel 
image depicting the effects of varied glucose concentration on IGF-II allelic expression in the PC3 cell line after 
48 h. Cells cultured in 9- and 25 mM glucose showed two bands sized 229 and 292 bp, indicating a change 
from mono- to biallelic IGF-II expression and, therefore, loss of imprinting. (n = 3). (D) Imprinting percentage 
change of PC3 cells after exposure to glucose for 6, 24 and 48 h. After 6 h, cells cultured in 25 mM glucose 
Figure 1. Genotyping, IGF-II allelic expression and imprinting behaviour after treatment with glucose, in prostate cancer cell
lines using APA1 RFL , PIE and qPCR analyses. (A) Gel image depicting genotype results of cell lines VcaP, DU145, PNT2,
LNCaP and PC3. VcaP and PC3 showed two bands, sized 292- and 229 bp. This meant that these cells were heterozygous
for the SNP at rs680 and, therefore, informative. (n = 3). (B) Gel image depicting IGF-II allelic expression. The VcaP cell line
showed two ba s, sized 292 and 229 bp, signifying bi-allelic expression and, therefore, loss of imprinting of IGF-II. The
PC3 cell line showed a single band sized 292 bp, indicati g m -allelic expression f IGF-II and, therefore, a retention of
imprinting status. (n = 3). (C) Gel image depicting the effects of varied glucose concentration on IGF-II allelic expression in
the PC3 cell line after 48 h. Cells cultured in 9- and 25 mM glucose showed two bands sized 229 and 292 bp, indicating
a change from mono- to biallelic IGF-II expression and, therefore, loss of imprinting. (n = 3). (D) Imprinting percentage
change of PC3 cells after exposure to glucose for 6, 24 and 48 h. After 6 h, cells cultured in 25 mM glucose showed a highly
significant (p < 0.001) decrease in imprinting percentage compared to those cultured in 5mM glucose. After 24 h, cells
cultured in 9 and 25 mM glucose showed significant decreases in imprinting percentage (p = 0.01 and p < 0.001, respectively),
when compared to those cultured in 5 mM glucose. After 48 h, cells cultured in 9 and 25 mM glucose showed highly
significant decreases in imprinting percentage (p < 0.001 and <0.001 respectively), when compared to those cultured in
5 mM glucose. (n = 3). I IGF-II and H19 mRNA relative expression in the PC3 cell line, after exposure to increased glucose
levels; a significant increase in IGF-II mRNA expression (i) was observed after 6, 24 and 48 h in 9 and 25 mM glucose media.
A significant decrease in H19 mRNA expression (ii) was observed after 48h in 9- and 25 mM glucose media. ** p = 0.01 and
*** p < 0.001)
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2.2. Confirmation of IGF-II Imprinting Status in the PC3 and VCaP Cell Lines
The PC3 and VCaP cell lines were then analysed further to establish IGF-II imprinting
status; RNA was extracted, converted to cDNA, and genotyped as before using the same
primers. The VCaP cell line produced two bands of sizes 292 and 229 bp, confirming bi-
allelic expression of IGF-II (IGF-II mRNA transcribed from 2 alleles: maternal and paternal)
and, therefore, loss of imprinting (Figure 1B). The PC3 cell line, produced a single band of
size 292 bp, indicating mono-allelic expression of IGF-II (IGF-II mRNA transcribed from a
single allele) and hence the retention of imprinting status and, therefore, considered to be
the most suitable cell line for experiments examining the induced loss of imprinting.
2.3. The Impact of Altered Levels of Glucose on IGF-II Imprinting Status
To investigate the effects of altered metabolic conditions upon IGF-II imprinting
status, we initially varied glucose levels in the culture media, to mimic conditions of a
hyperglycaemic environment. PC3 cells were cultured in 5, 9 and 25 mM glucose media for
6, 24 and 48 h. RNA was extracted, converted to cDNA and genotyped as before. After 48 h,
cells exposed to 9 and 25 mM glucose-containing media, showed two bands of 229 and
292 bp. This indicated a change from mono- to biallelic IGF-II expression and, therefore,
loss of imprinting (Figure 1C).
2.4. The Impact of Altered Levels of Glucose on IGF-II Imprinting Percentage
To further clarify the change in imprinting status, pyrosequencing was used to quantify
the loss of imprinting as a percentage. Using the SNP assay facility, within the Qiagen
Pyromark Q96 software, it was possible to genotype and calculate imprinting loss using
the A/G SNP at rs680. We applied the formula: 2 (A-50), where A > 50, or 2 (50–A),
where A < 50. After 6 h, cells cultured in 25 mM glucose showed a significant (p < 0.001)
decrease in imprinting percentage, compared to those cultured in 5 mM glucose. After 24 h,
cells cultured in both 9 and 25 mM glucose showed significant decreases in imprinting
percentage (p = 0.01 and p < 0.001, respectively), compared to those cultured in 5 mM
glucose; the effects of 9and 25 mM glucose were enhanced further after 48 h (p < 0.001 and
0.001, respectively) when compared to those cultured in 5 mM glucose (Figure 1D).
2.5. The Impact of Altered Levels of Glucose on IGF-II mRNA Expression
To ascertain whether changes in imprinting status and percentage, induced by in-
creasing glucose levels, were accompanied by changes in IGF-II (Figure 1Ei) and H19
(Figure 1Eii) mRNA expression, qPCR was used to quantify relative expression of both
using GAPDH as the internal control/house-keeping gene. After 6 h, there was a significant
decrease in IGF-II mRNA in cells cultured in 9 mM and 25 mM glucose media (p = 0.01 and
p < 0.001 respectively), when compared with the control (5 mM glucose). There were no
significant changes to H19 mRNA expression. The same pattern of IGF-II expression was
observed after 24 h (p < 0.001and 0.001, respectively) when compared with the control
and similarly there were no significant changes in H19 mRNA expression. After 48 h,
however, there was a significant increase in IGF-II mRNA in cells cultured 25 mM glucose
media (p = 0.01), when compared with the control. Conversely, a significant decrease in
H19 mRNA expression was observed, in cells cultured in 9 mM and 25 mM glucose media
(p < 0.001 and 0.001, respectively).
2.6. Effects of TNFα on IGF-II Imprinting Status
Having established the effects of glucose on IGF-II imprinting, we next investigated
the effects of an inflammatory cytokine. PC3 cells were cultured in 5- and 25 mM glucose
media and exposed to increasing doses (0 to 10 ng/mL) of tumour necrosis factor-alpha
(TNFα) for 24 h. RNA was extracted and genotyped as before. Cells cultured in 5 mM
glucose and dosed with 10 ng TNFα showed two bands sized 229 and 292 bp, which
indicated a change from mono- to biallelic IGF-II expression, suggesting loss of imprinting
(Figure 2Ai). Cells cultured in 25 mM glucose-containing media and dosed with 1, 5, and
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10 ng/mL ng TNFα showed two bands sized 229 and 292 bp. This indicated a change from
mono- to biallelic IGF-II expression, suggesting loss of imprinting. The untreated cells,
cultured in 25 mM glucose also showed two bands of 229 and 292 bp, confirming the loss
of imprinting with raised glucose (Figure 2Aii).
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Figure 2. IGF-II allelic expression, imprinting behaviour and peptide expression after treatment with TNFα, in prostate
cancer cell lines using APA1 RFLP, PIE, qPCR and RIA analyses. (A) Gel image depicting the effects of TNFα upon IGF-II
allelic expression in the PC3 cell line, after 24 h exposure. Cells cultured in 5mM (i) glucose and dosed with 10 ng/mL
TNFα showed two bands, sized 229 and 292 bp, indicating a change from mono- to biallelic IGF-II expression and, therefore,
loss of imprinting. Cells cultured in 25 mM (ii) glucose and dosed with 0, 1, 5 and 10 ng/mL TNFα showed two bands sized
229 and 292 bp, indicating a change from mono- to biallelic IGF-II expression and, therefore, loss of imprinting. (n = 3).
(B) Imprinting percentage change of PC3 cells after exposure to TNFα for 24 h in 5 mM (i) and 25 mM (ii) glucose. Cells
cultured in 5 mM glucose media (i) and dosed with 1, 5 and 10 ng/mL TNFα all showed highly significant (p < 0.001)
decreases in imprinting percentage; those cultured in 25 mM glucose media (ii) and dosed with 5 and 10 ng/mL TNFα,
also showed highly significant (p < 0.001) decreases in i printing percentage when compared with the control. (n = 3).
(C) IGF-II and H19 mRNA relative expression in the PC3 cell line, after tre tment with TNFα in 5 mM (i) and 25 mM (ii)
glucose for 24h, using qPCR; (i) a ignifica t increase in IGF-II was observed in c lls dosed with 1, 5 and 10 ng/mL TNFα.
No significant fold changes in H19 mRNA were observed (n = 3). (ii) No significant fold changes in IGF-II mRNA were
observed. A significant decrease in H19 as observed in cells dosed with 1ng/mL TNFα, whilst a significant increase was
observed in those dosed with 10ng/mL TNFα. (D) The effects of glucose and TNFα upon IGF-II peptide after 24 and 48 h
exposure to 5 mM (i) and 25 mM glucose (ii) combined with increasing doses of TNFα, quantified using RIA. There were
no significant changes in the quantities of IGF-II peptide. after 24 and 48 h exposure to 5 (i) or 25 mM (ii) glucose, when
combined with increasing doses of TNFα. (n = 3). (* p = 0.05, ** p = 0.01 and *** p < 0.001)
2.7. Effects of High Dose TNFα on the Degree of IGF-II Imprinting in Cells Cultured in Normal
(5mM) Glucose Media
To assess the effects of TNFα upon imprinting percentage, pyrosequencing was used.
Cells cultured in 5 mM glucose (Figure 2Bi) and dosed with 1, 5 and 10 ng/mL all showed
significant (p < 0.001) decreases in imprinting percentage, compared to controls. Cells
cultured in 25 mM glucose (Figure 2Bii) and dosed with 5 and 10 ng/mL TNFα both showed
highly significant decreases in imprinting percentage (p < 0.001 and 0.001, respectively)
whe compared to cont ols.
2.8. Effects of TNFα on IGF-II mRNA Expression in Cells Cultured in Normal (5 mM)
Glucose Media
To scertain whether changes in imprinting status and percentage, induced by TNFα,
were accompanied by changes in IGF-II and H19 mRNA expression, qPCR was conducted.
Cells cultured in 5 mM glucose media showed a significant decrease in IGF-II mRNA
expression when dosed with 1 and 5 ng/mL TNFα (p = 0.01 and 0.05, respectively),
compared with the untreated control. In contrast, cells treated with 10 ng/mL TNFα
showed a s gnificant (p = 0.01) increase in IGF-II mRNA expression, when compare
with the control. No significant fold changes in H19 mRNA expression were recorded
(Figure 2Ci).
Cells cultured in 25mM glucose showed no significant changes in IGF-II mRNA
when compared to the untreated control. Conversely, a significant decrease (p = 0.01) in
H19 mRNA was observed in cells treated with 1 ng/mL TNFα, compared to the un-dosed
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control. A significant increase (p < 0.001) in H19 mRNA was observed in cells treated with
10 ng/mL of TNFα when compared with the un-dosed control (Figure 2Cii).
2.9. Effects of TNFα on Levels of Secreted IGF-II Peptide
Having observed the influence of TNFα on IGF-II mRNA expression, we next investi-
gated whether this translated into the secreted peptide. Conditioned media from the TNFα
dosing experiments was collected and quantified for peptide using radioimmunoassay
(RIA). Cells cultured in 5 mM glucose and exposed to increasing doses of TNFα (0, 1,
5 and 10 ng/mL) for 24 and 48 h, showed no significant changes to secreted IGF-II peptide
(Figure 2Di). This was also true of cells cultured in 25 mM glucose, exposed to identical
doses of TNFα after identical time points (Figure 2Dii).
2.10. IGF-II Imprinting Status Does Not Significantly Vary Between Benign and Malignant
Paired Prostate Tissue Samples
After examining imprinting behaviour in vitro, we next compared imprinting status in
prostate tissue samples. For this, prostate tissue from a large clinical cohort, previously col-
lected for the PrEvENT study (ISRCTN reference number ISRCTN99048944) [38] was used.
Total RNA was extracted from formalin-fixed paraffin-embedded (FFPE) specimens and
pyrosequenced to clarify imprinting status (defined by Qiagen Pyromark Q96 software),
and imprinting loss as a percentage. 84 patients from the PrEvENT cohort had representa-
tive paired samples of benign and malignant tissue. Peak heights at A/G rs680 SNP were
converted into percentages. Tissue was typed as eith“r "maintaining imprinting sta”us"
(MOI) “r "loss of imprinting sta”us" (LOI). Figure 3A depicts the total cohort with propor-
tional representation of each tissue pairing; out of 84 patients 64 presented with no change
of MOI status (in the benign sample compared to its cancer counterpart), 6 presented
with a change in status from MOI to LOI, 7 presented with a change in status from LOI
to MOI and 7 presented with no change of LOI status. Figure 3B shows the percentage
imprinting within each genotype grouping. The group containing the 6 paired samples,
with LOI in cancer compared with MOI in the benign tissue, showed a significant decrease
(p < 0.001) in imprinting percentage. The group containing the 7 paired samples, with MOI
in cancer compared with LOI in the benign tissue showed a significant increase (p < 0.001)
in imprinting percentage.
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Figure 3. Imprinting status of paired benign and malignant prostate tissue samples from the PrEvENT
cohort. (A) Cohort divided by imprinting status change, moving from benign to corresponding
malignant counterpart. Of the total cohort (84 tissue pairs), 64 showed no change of maintenance
of imprinting (MOI) from benign to malignant; 7 showed no change of loss of imprinting (LOI),
from benign to malignant; 6 showed a change from LOI to MOI and 7 showed a change from
MOI to LOI. (B) Imprinting status sub-divisions of PrEvENT cohort, with changes in imprinting
percentage. A significant decrease (p < 0.001) in imprinting percentage was seen in samples where
imprinting status changed from MOI to LOI (n = 7); conversely, a significant increase (p < 0.001)
in imprinting percentage was seen in samples where imprinting status changed from LOI to MOI
(n = 6). (B = benign tissue, C = cancer tissue) (*** p < 0.001)
2.11. There Is a Positive Correlation Between IGF-II and H19 mRNA Expression in Benign and
Malignant Prostate Tissue
We used ddPCR to quantify relative expression of mRNA for IGF-II and H19 in sam-
ples from the PrEvENT cohort, in both benign and malignant tissue, using housekeeping
gene G2/M phase-specific E3 ubiquitin-protein ligase (G2E3). There was no difference in
absolute expression of IGF-II or H19 between benign and malignant tissue. However, we
did observe a positive correlation between IGF-II and H19 expression; with a significant
weak positive correlation (Pearson: R = 0.28, p = 0.01) in the benign tissue (Figure 4Ai) and a
stronger positive correlation in malignant prostate tissue (R = 0.67, p < 0.0001) (Figure 4Aii).
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Figure 4. Co-expression of IGF-II & H19 mRNA and IGF-II & % imprinting in benign and prostate
cancer tissue sections. (A) Co-expression of H19 & IGF-II mRNA in benign (i) and cancer (ii) derived
from FFPE prostate tissue from the PrEvENT cohort. Pearson’s corr lation coefficient analysis found
a significant (p = 0.01) weak positive (R = 0.28) correlation between H19 and IGF-II mRNA expression
in benign prostate tissue; a significant (p < 0.001) stronger (R = 0.67) positive correlation was found
in cancer tissue (n = 95). (B) Metabric data from The Cancer Genome Atlas (TGCA) showed strong
p sitive correlations between co expressio of H19 & IGF-II mRNA in (i) pro tate (R = 0.6, p < 0.001)
(i) and (ii) breast (R = 0.64, p < 0.001 cancer. (C) Imprinting percentage of IGF-II gene plotted against
IGF-II mRNA in (i) benign and (ii) cancer prostate tissue. A significant positive correlation was seen
between IGF-II imprinting percentage and mRNA expression in both tissue types. (n = 84).
After quantifying IGF-II and H19 mRNA expression in the PrEvENT cohort, we
utilised the cBioPortal for Cancer Genomics website to assess whether co-expression of
IGF-II and H19 mRNA existed, in a larger prostate cancer cohort, as well as another
hormone-responsive cancer type: breast.
In the prosta e cohort—provid d by the Cancer Genome Atlas (TGCA)—a strong pos-
itive correl t o (Pear on: 0.6) was seen in the co-expression of H19 and IGF-II (p < 0.001)
with 489 patients (Figu e 4Bi). Similarly, in the TGCA breast cancer cohort (Figur 4Bii), a
strong positive rrelation (Pearson: 0.64) was lso seen in the co- xpre sion of H19 and
IGF-II (p < .001) with 994 patients.
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2.12. There is a Positive Correlation between IGF-II mRNA and the Degree of Imprinting in
Benign and Malignant Prostate Tissue
To identify whether IGF-II mRNA expression correlates with imprinting percentage in
the PrEvENT cohort, ddPCR data was plotted against imprinting percentages; a significant
(p = 0.05) positive correlation (R = 0.328) was found in benign prostate tissue (Figure 4Ci),
which was marginally weaker in malignant tissue (p = 0.05 and R = 0.224) (Figure 4Cii).
2.13. Levels of IGF-II Peptide Do not Differ between Benign and Malignant Prostate Tissue
Having analysed IGF-II mRNA expression in the PrEvENT cohort, we then assessed
the abundance of peptides; sections were taken from FFPE tissue specimens and stained
for IGF-II peptide, using immunohistochemistry (IHC). The Allred scores of IGF-II pep-
tide abundance in benign and cancerous prostate tissue (n = 94) showed no significant
differences in stain intensity and proportion (Figure 5A). Micrograph images (Figure 5B)
illustrate strong IGF-II peptide staining in cancer (image A) and benign (image D) tissues,
and weak staining in cancer (C) and benign (B) tissues.
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in staining scores between malignant and benign. (B) Patterns of IGF-II cytoplasmic IHC staining in paired tissue samples 
from 2 patients. Strong IGF-II peptide staining was observed in both cancer (A) and benign (D) tissue, as was weak staining 
(B/benign & C/cancer). The scale is 1 × 1 mm, at 20× magnification. 
3. Discussion 
Loss of imprinting in the growth factor, IGF-II, is a phenomenon common to many 
different cancer types [39]. The causes and consequences remain unclear. If modifiable 
behaviours can be shown to influence its occurrence, this could have important implica-
tions for understanding the development and progression of cancers. 
In this study, we have demonstrated that under either hyperglycaemic or inflamma-
tory metabolic conditions, loss of IGF-II imprinting can be induced in vitro. In high glu-
cose (i.e above the healthy range of 4 to 5.9 mM/L for an adult according to NICE guide-
lines (The National Institute for Health and Care Excellence, 2012) or increased inflamma-
tory (TNFα 10 ng/mL) conditions, IGF-II loses imprinting with the introduction of gradual 
expression of the silenced copy. However, the marked increase in mRNA did not translate 
into an increased expression of IGF-II peptide. 
Whilst the exact mechanism of imprinting loss is unclear it may be hypothesised that 
exposure to elevated glucose conditions and/or inflammatory cytokines may disrupt the 
methylation patterns in and around the IGF-II/H19 locus. Our in vitro data indicated that 
LOI was accompanied by an increase in expression of IGF-II and a reciprocal reduction in 
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IHC staining of IGF-II peptide i FFPE prostate tumour tissue using the Ventan Benchmark U tra
machine. There were no was no significant differences in staining scores between malignant and
benign. (B) Patterns of IGF-II cytoplasmic IHC staining in paired tissue samples from 2 patients.
Strong IGF-II peptide staining was observed in both benign (A) and cancer (D) tissue, as was weak
staining (B/benign & C/cancer). The scale is 1 × 1 mm, at 20×magnification.
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3. Discussion
Loss of imprinting in the growth factor, IGF-II, is a phenomenon common to many
different cancer types [39]. The causes and consequences remain unclear. If modifiable
behaviours can be shown to influence its occurrence, this could have important implications
for understanding the development and progression of cancers.
In this study, we have demonstrated that under either hyperglycaemic or inflammatory
metabolic conditions, loss of IGF-II imprinting can be induced in vitro. In high glucose (i.e.,
above the healthy range of 4 to 5.9 mM/L for an adult according to NICE guidelines (The
National Institute for Health and Care Excellence, 2012) or increased inflammatory (TNFα
10 ng/mL) conditions, IGF-II loses imprinting with the introduction of gradual expression
of the silenced copy. However, the marked increase in mRNA did not translate into an
increased expression of IGF-II peptide.
Whilst the exact mechanism of imprinting loss is unclear it may be hypothesised that
exposure to elevated glucose conditions and/or inflammatory cytokines may disrupt the
methylation patterns in and around the IGF-II/H19 locus. Our in vitro data indicated that
LOI was accompanied by an increase in expression of IGF-II and a reciprocal reduction in
expression of H19 consistent with the "enhancer competition model", first posited in 1993 by
Bartolomie et al. [29]. Further pyrosequencing to analyse methylation patterns may provide
further clarification. Exposure of bovine kidney epithelial cells to butyrate also resulted in
increased expression of IGF-II and reduced expression of H19, although the mechanism,
in that case, may be more straightforward, as butyrate is a known epigenetic regulator
due to its activity as an inhibitor of histone deacetylases, increasing global acetylation [40].
Oxidative stress can also induce loss of imprinting, in both benign and malignant prostate
tissue, by disrupting the expression of CTCF and its binding to H19 and the ICR [41].
In the PrEvENT cohort, most matched benign and malignant specimens showed no
change in imprinting status, with MOI being most prevalent in both tissue types. This
disagrees with findings that have shown LOI to be more common in prostates associated
with cancer [42], however, our results were limited by the relatively small cohort size.
In contrast to our in vitro findings, we demonstrated a positive correlation between
IGF-II and H19 mRNA expression in the prostate tissue; whilst this was weaker in benign
tissue, the stronger positive correlation—seen in malignant tissue—concurred with that of
the larger TGCA prostate and breast cancer cohorts.
Our in vitro findings may be explained by the use of the PC3 cell line—a cultured
monolayer of cells, of a single cell type—compared to the use of clinical tissue specimens,
which conversely, are greatly heterogeneic in nature, as shown by Küffer et al. in their
work [37].
Interestingly, IGF-II / H19 LOI is also found in normal tissue and not just cancer,
where frequently it is also not related to expression levels. For example, 22% of normal
infants have IGF-II LOI with no changes in expression levels in the majority [43]. We
suggest that imprinting is only one factor in regulating expression and may not be that
important in human tissues; IGF-II and H19 share a common enhancer 3′-downstream
from H19 [44] that could be a more important determinant of expression of both, rather
than imprinting controls.
The key finding that bridges our in vitro with in vivo findings is that there was no
measurable change in IGF-II peptide. The lack of correlative findings may be explained by a
deficiency of RNA binding proteins. One such group of binding proteins are the insulin-like
growth factor 2 messenger-RNA binding proteins (IMPs). These affect the processing of
IGF-II mRNA at multiple levels including translation. Of the three IMPs (IMP1, IMP2 and
IMP3) identified [45], IMP3 has been shown to activate translation of mRNA by binding to
the coding regions of IGF-II [46]. Under our simulated in vitro conditions, inhibition or
insufficient synthesis of IMP3 may have occurred and further quantification of IMP3 would
address this issue.
In vivo, a deficiency of RNA binding proteins may be also contributory, but an ad-
ditional factor may be that circulating IGF-II peptide is unstable and may be susceptible
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to degradation [47]. To combat this, it binds with specific binding proteins—insulin-like
growth factor binding proteins (IGFBPs). There are six IGFBPs: IGFBP1-6 and they bind
to IGF-I and -II with high affinity [48]. More specifically, IGFBP2 binds to IGF-II with
very high affinity [49]. Therefore, the inconsistency of IGF-II staining is likely due to the
presence of peptide bound to IGFBP-2.
Different associations have been reported between IGF-II LOI, mRNA and peptide
levels and this reflects the limited number of studies and the use of diverse methodologies
and assays. For example, one report in men with prostate cancer found no relationship
between IGF-II LOI status in circulating blood and serum IGF-II levels, whereas a rela-
tionship between the two existed in men without prostate cancer [36]. In contrast, IGF-II
peptide was increased in triple-negative breast tumours with LOI [50] and a relationship
between IGF-II levels in blood was found with LOI in gastric cancers [51].
4. Methods
4.1. Prostate Cell Lines
Immortalised prostate cancer cell lines PC3, LNCaP, DU145 and VCaP, and a nor-
mal prostate epithelial cell line—PNT2, were purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). PC3, VCaP and DU145 were grown and main-
tained in Dulbecco’s modified Eagles Medium (DMEM, BioWittaker, Verviers, Belgium)
supplemented with 10% foetal bovine serum (FBS, Gibco, Paisley, UK) and 1% L-glutamine
solution (2 mM; Sigma, Dorset, UK). LNCaP and PNT2 cell lines were grown and main-
tained in Roswell Park Memorial Institute (RPMI-1640, BioWittaker, Verviers, Belgium)
growth medium supplemented with 10% FBS and 1% L-glutamine solution, as before. Cells
were incubated at 37 ◦C, in a humidified 5% carbon dioxide environment.
4.2. Isolation of Nucleic Acids
DNA and total RNA were isolated using DNAzol® and RNAzol® (Invitrogen, Thermo
Fisher Scientific, Paisley, UK) reagents respectively, according to the manufacturer’s in-
structions.
DNA was resuspended in 40mM NaOH (Merck Life Science, Dorset, UK) and RNA
was resuspended in RNase-free water; both were quantified using a NanoPhotometerTM
(Implen, München, Germany). Extracts were stored at –20 ◦C and –80 ◦C, respectively.
4.3. Preparation of cDNA
RNA was treated with DNase I (Sigma-Aldrich, Gillingham, UK) prior to cDNA
conversion, using the High-Capacity RNA-to-cDNA Kit® (Applied Biosystems, Foster City,
CA, USA). cDNA was made from 2 µg RNA, as per kit protocol. The resulting product was
stored at –20 ◦C.
4.4. Genotyping of Cell Lines, Using Restriction Fragment Length Polymorphism (RFLP) Analysis
Cell DNA and RNA (cDNA) was genotyped by exploiting the presence of a single
nucleotide polymorphism (SNP) in exon 7 of IGF-II, at restriction site 680 (APA1). Cell lines
that were heterozygous for this SNP at the DNA level were then used to identify whether
IGFII mRNA (cDNA) was transcribed from one or two alleles. The RFLP process was
conducted in two stages: The first amplified IGF-II product via PCR, using the following
primer sequences: F cttggactttgagtcaaattgg and R ggtcgtgccaattacatttca (Sigma-Aldrich).
The second stage used an APA1 digestion enzyme (catalogue no. FD1414, Thermo Fisher
Scientific), as per kit protocol, to digest product from stage 1 and “cut” at rs680. The
resulting products were run on a 2% agarose (Bio-Rad, Hercules, CA, USA) gel and
visualised using a trans-illuminator (Bio-Rad).
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4.5. Dosing Experiments
For all experiments, cells were seeded at a density of 1× 106 million cells per T25 flask
(Greiner Bio-one, Gloucestershire, UK) in normal glucose-containing medium (1000 mg/L–
5 mM). After 24 h, media was exchanged for serum-free media (SFM) supplemented with
sodium bicarbonate (1 mg/mL) (Sigma-Aldrich), bovine serum albumin (0.2 mg/mL,
Sigma-Aldrich) and apo-transferrin (0.01 mg/mL) (Sigma-Aldrich), with normal glucose
(5 mM), moderate glucose (9 mM) and high glucose SFM (25 mM).
At 6, 24 and 48 h intervals, a flask from each different glucose concentration was
removed and processed for RNA extraction. At the end of each time point, there were
3 flasks containing 5 mM, 9 mM and 25 mM SFM.
For TNFα dosing, cells were seeded in 5 mM glucose-containing DMEM. After 24 h,
media was replaced with 5 mM and 25 mM glucose SFM. 24 h later, cells were dosed with
or without TNFα at 1, 5 and 10 ng/mL, respectively. Cells were processed for RNA and
DNA extraction.
4.6. Quantitative PCR (qPCR)
qPCR was performed using SYBR Green (Applied Biosystems) on a StepOne Real-
Time PCR machine (Thermo Fisher Scientific). GAPDH was used as an internal con-
trol. Primer sequences were as follows: GAPDH F-CATCTTCTTTTGCGTCGCCA and R-
TTAAAAGCAGCCCTGGTGACC, IGF-II F- GAGCTCGAGGCGTTCAGG and R-GTCTTGG
GTGGGTAGAGCAATC and H19 F-CGGAACATTGGACAGAAG and R-GGCGAGGCAG
AATATAAC (Sigma-Aldrich). Quantitation of product was conducted using the Quantita-
tion Comparative CT function within StepOne software (ThermoFisher Scientific). Relative
expression was calculated using the Pfaffl method [52].
4.7. Pyrosequencing
Preparation of cDNA for pyrosequencing was conducted as previously described [53],
with the nested PCR step scaled up four-fold to yield 40 µl product as per assay re-
quirements defined by the Qiagen Pyromark Q96 protocol. Two sets of primers were
used, with the following sequences: Set 1) F- ATCGTTGAGGAGTGCTGTTTCC & R-
GAGCCAGTCTGGGTTGTTGC; Set 2/Nested) F- AGTCCCTGAACCAGCAAAGAG &
R-biotin-TCGGATGGCCAGTTTACC; the pyrosequencing primer sequence was as follows:
AGCAAAGAGAAAAGAAGG (Eurofins). The PCR product was prepared for pyrose-
quencing using Qiagen PyroMark Gold Q96 reagents and buffers (Qiagen, Manchester,
UK) and sequenced on a PyroMark Q96 machine (Qiagen) by kind permission of Cardiff
University Hospital, Cardiff, Wales – UK and North Bristol NHS Trust, Department of
Pathology, Southmead Hospital, Bristol, UK. Peak heights and genotypes were quantified
by the Qiagen Pyromark software SNP application; peak heights at the rs680 A/G SNP
were converted to imprinting percentages using the following formulae: Where A > 50%: 2
(A-50). Where A < 50%: 2 (50-A).
4.8. Radioimmunoassay (RIA)
The concentration of IGF-II peptide was quantified in-house, using radioimmunoassay
(RIA) as previously described [54]. This method quantifies all forms of IGF-II peptide,
including those that have undergone fragmentation.
4.9. Immunohistochemistry (IHC)
Using a microtome (Leica), 8 µm thick slices were taken from formalin-fixed paraffin-
embedded (FFPE) prostate tissue blocks and mounted on Tomo microscope slides (Mat-
sunami, Bellingham, WA, USA). Slides were then stained for IGF-II peptide using an
IGF-II antibody (AbCam, Cambridge, UK) at a dilution of 1:600, on a Ventana BenchMark
ULTRA™ machine (Roche, Oro Valley, AZ, USA). Slides were scored by two pathologists
using a modified version of the Allred system, combining the proportion of tissue stained
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(a scale of 1–5) with the staining intensity (a scale of 1–3) to give a score out of 8 [55].
Currently, there is no standardized method of scoring prostate tissue.
4.10. Digital Droplet PCR (ddPCR)
Primers and Taqman probes were purchased from Bio-Rad and Thermo Fisher Scien-
tific; to optimize the detection of total IGF-II and H19 transcript expression with ddPCR,
we initially performed an annealing temperature gradient test for our assay using the
prostate cancer cell line PNT2 total RNA. At 55 ◦C, annealing temperature for ddPCR
reactions total IGF-II and H19 amplicon-containing droplets showed the best separation
between positive and negative clusters. DDPCR samples for total IGF-II and H19 were set
up with 16ng cDNA samples from individual patients; a stock mix was prepared which
contained 10 µL ddPCR Supermix for Probes, no dUTP (Bio-Rad), 500 nM of each forward
and reverse primer (FP and RP) and 250 nM probe (FAM and HEX). Each reaction volume
totalled 20 µL. Droplets were generated with 70 µL oil using a QX200 droplet generator
(Bio-Rad). Amplification was performed at 95 ◦C, 10 min; followed by 40 cycles of 94 ◦C,
30 s and 55 ◦C, 1 min using a C1000 Touch thermocycler (Bio-Rad). After amplification,
the droplets were read on a QX200 droplet reader (Bio-Rad) and analysed with Quan-
taSoft software V1.7.4 (Bio-Rad), which converted droplets to copies/ng RNA based on
the RNA concentration and the total volume added to the reaction dependent on Poisson
distribution. For normalized expression, we used the ratio of IGF-II/H19 concentration to
an internal/housekeeping control G2E3 concentration. Raw fluorescence amplitude data
were extracted from the droplet reader. We excluded/repeat samples which had too many
positive or negative droplets or less than 10,000 droplets.
4.11. Use of cBioPortal for Cancer Genomics to Examine co-expression of IHG-II & H19 mRNA
One representative Cancer Genome Atlas cohort was selected from the list of breast
and prostate cancer studies. Each cohort was assessed for the availability of IGF-II and
H19 mRNA co-expression data, which had been gathered using the Illumina HiSeq se-
quencing system.
4.12. Statistical Analysis
Analysis of variance (ANOVA) was used for in vitro data, where comparative control
experiments were conducted; error bars show the standard error of the mean. A two-
tailed t-test was used for in vivo data, to compare the differences between two groups.
For correlation analyses, the Pearson correlation coefficient was calculated, with results
being expressed as an R-value. P values are denoted as follows: * p = 0.05, ** p = 0.01 and
*** p < 0.001.
5. Conclusions
Our study illustrated that an artificially simulated inflammatory environment does
induce loss of imprinting in IGF-II, causing upregulation of IGF-II and downregulation
of H19 mRNA. The potential cause may be due to disruption of methylation patterns
throughout both copies of the gene, inducing partial expression of the usually silenced
paternal copy. The increase in IGF-II mRNA did not equate to elevated protein expression
which may be due to impaired RNA-binding protein synthesis. Matched benign and
malignant specimens from the PrEvENT cohort primarily retained imprinting status,
although a small subset with LOI did exhibit reduced imprinting. A positive correlation
was seen between IGF-II and H19 mRNA expression, which concurred with findings of
larger TGCA cohorts and other hormone-responsive cancer types (breast). This positive
correlation did not affect IGF-II peptide. Our in vitro findings are of utmost relevance to
indicate that type 2 diabetes and/or obesity directly affect the regulation of growth factors
involved in carcinogenesis. Furthermore, our data suggest that LOI does not necessarily
coincide with the development of cancer or translate into more IGF-II peptide, but its actual
consequences may only be fully understood when the complex interactions between all
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the products of the gene locus, including long non-coding RNA, microRNA and antisense
transcripts, are fully characterised.
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